BARDA is seeking to partner with laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays to support advanced research and development of influenza and emerging infectious disease vaccines using samples collected from nonclinical studies and clinical trials. Additionally, the central immunoassay laboratory will provide rapid response capability to qualify/validate immune assays for newly emerged viral strains or variants and test clinical and/or nonclinical samples in an accelerated fashion in the event of an influenza virus outbreak. Data from these assays may be used in primary, secondary, and exploratory endpoint analyses for vaccine clinical trials, cross-reactivity testing for pandemic readiness and response purposes or perform correlates of protection analyses.

All RRPV submissions must be submitted to the BARDA Digital Resources (BDR) RRPV Portal. Offerors may submit, or re-submit, in advance of the deadline. Neither the Government nor the RRPV CMF will make allowances/exceptions for submission problems encountered by the Offeror using system-to-system interfaces. If the Offeror fails to submit the full submission prior to the deadline, the submission may not be accepted. It is the Offeror’s responsibility to ensure a timely and complete submission. Failure to propose your submission on time for any reason may result in the submission not being considered for award.

The account request process is simple but may take several days for approval and access. To request a BDR RRPV Portal account (first-time user), please contact the RRPV (RRPV@ati.org) and provide a set of basic information (first and last name, email address, and phone number, member organization). Once access to the BDR RRPV Portal account has been confirmed, the Offeror will log in to the Portal (www.rrpv.hhs.gov) using the prescribed two-factor authentication method. Once login is complete, the Offeror will be prompted to verify their user information and basic organization-related data. To request changes to your contact information, please contact RRPV (RRPV@ati.org). The Offeror will then be able to start a new submission and will be prompted to input the submission with other project-specific information. Offerors will be provided an automated confirmation of successful submission of a Proposal.

Documentation and reference materials for the BDR RRPV Portal are available to RRPV Member Organizations from the RRPV Members Only Site (for new users, request access here), and upon request from RRPV@ati.org.

Amendment 02 RPP Release:

Issued: 04/11/2025

Updates: Revises the Mandatory Eligibility Criteria and rearranges existing capability areas for assay development and sample testing and adds three new capability areas for potency reagent preparation, assay concordance, and technology transfer.

Questions Due: 04/24/2025, by 12PM EST

Proposals Due: 05/30/2025, by 1PM EST

Amendment 01 RPP Release:

Issued: 06/28/2024

Original RPP Release:

Issued: 06/14/2024